CDEK
← All drugs Report issue

Azvudine

Small moleculeexperimental

Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. It was discovered for the treatment of hepatitis C and has since been investigated for use against other viral diseases such as AIDS and COVID-19, for which it was granted conditional approval in China. — Wikipedia

Clinical trial activity

20 trials · 21 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
6
Phase 3
6
Phase 4
1

Earliest trial started Oct 10, 2017 (NCT04109183)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07307586Phase 3Sep 1, 2025Zhengzhou University
NCT07001436Phase 1May 20, 2025Government of China
NCT07002281Phase 1Jul 22, 2024Government of China
NCT06991634Phase 1Apr 8, 2023Government of China
NCT05697055Phase 4Jan 21, 2023Gansu Provincial Hospital, People's Hospital of Rizhao, Shandong first medical University, Shandong Province Qianfoshan Hospital, Shandong Provincial Hospital, Southwest Medical University
NCT05689034Phase 2/Phase 3 (Phase 3)Jan 20, 2023Chinese Academy of Medical Sciences
NCT05682599Phase 2Jan 6, 2023Fosun, Fudan University, HeNan Sincere Biotech Co., Ltd, Shanghai Henlius Biotech
NCT05633433Phase 2/Phase 3 (Phase 3)Dec 15, 2022Fosun, Government of China, HeNan Sincere Biotech Co., Ltd, Shanghai Henlius Biotech
NCT05642910N/AOct 18, 2022Southeast University
NCT07002242Phase 1Jul 6, 2022Government of China
NCT07002268Phase 1Mar 14, 2022Government of China
NCT07001488Phase 1Feb 21, 2022Government of China
NCT07001501Phase 1Feb 21, 2022Government of China
NCT07002255Phase 1Dec 20, 2021Government of China
NCT07002229Phase 1Dec 9, 2021Government of China
NCT05033145Phase 3Oct 31, 2021Galzu Institute, HRH Pharmaceuticals Limited
NCT04668235Phase 3Dec 31, 2020Galzu Institute, HRH Pharmaceuticals Limited, Santa Casa de Misericordia de Santos, UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE (UENF), Brazil
NCT04425772N/AJun 12, 2020HeNan Sincere Biotech Co., Ltd
NCT04303598Phase 3Apr 1, 2020HeNan Sincere Biotech Co., Ltd
NCT04109183Phase 2Oct 10, 2017Capital Medical University, Chinese Academy of Medical Sciences, Guangzhou Medical University, HeNan Sincere Biotech Co., Ltd, The Sixth People's Hospital of Zhengzhou
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (21)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment10922021
HeNan Sincere Biotech Co., LtdFor profit5332017
Chinese Academy of Medical SciencesAcademic/Hospital2122017
FosunFor profit2022022
Galzu InstituteAcademic/Hospital2012020
HRH Pharmaceuticals LimitedFor profit2212020
Shanghai Henlius BiotechFor profit2222022
Capital Medical UniversityAcademic/Hospital1012017
Fudan UniversityAcademic/Hospital1012023
Gansu Provincial HospitalAcademic/Hospital1012023
Guangzhou Medical UniversityAcademic/Hospital1012017
People's Hospital of RizhaoAcademic/Hospital1012023
Santa Casa de Misericordia de SantosAcademic/Hospital1012020
Shandong first medical UniversityAcademic/Hospital1012023
Shandong Province Qianfoshan HospitalAcademic/Hospital1012023
Shandong Provincial HospitalAcademic/Hospital1112023
Southeast UniversityAcademic/Hospital1112022
Southwest Medical UniversityAcademic/Hospital1012023
The Sixth People's Hospital of ZhengzhouAcademic/Hospital1012017
UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE (UENF), BrazilAcademic/Hospital1012020
21 organizations
Page 1 / 2